Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.

Matthew SheetzPhilip BarringtonSophie CalliesPaul H BergJuliet McColmThomas MarburyBrian DeckerGregory L DyasStephanie M E TruhlarRobert BenschopDonmienne LeungJolene BergDerrick R Witcher

Published in: British journal of clinical pharmacology (2019)

LY3113593 and LY2928057 pharmacological effects (serum iron and ferritin) were translated from preclinical-to-clinical development. Such interventions may lead to new CKD anaemia treatments.

Keyphrases

iron deficiency
chronic kidney disease
end stage renal disease
physical activity
cancer therapy
cell therapy
stem cells
peritoneal dialysis
bone marrow